Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.5%

2 terminated out of 31 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

6%

1 of 16 completed with results

Key Signals

1 with results89% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (5)
P 1 (5)
P 2 (6)
P 3 (2)

Trial Status

Completed16
Unknown6
Recruiting4
Not Yet Recruiting2
Terminated2
Active Not Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT07391007Not Yet RecruitingPrimary

Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases

NCT06501482Phase 3Recruiting

Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI

NCT06848842Phase 2RecruitingPrimary

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

NCT07117435Phase 1RecruitingPrimary

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

NCT06779474Not Yet RecruitingPrimary

Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

NCT04161092Not ApplicableActive Not Recruiting

The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases

NCT05468593CompletedPrimary

Patient Outcomes After Hepatic Artery Infusion Pump Placement

NCT05265169Not ApplicableRecruitingPrimary

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

NCT06045286Phase 1UnknownPrimary

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM

NCT05877001Phase 2UnknownPrimary

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

NCT02082782Phase 2CompletedPrimary

Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases

NCT01799044Phase 1CompletedPrimary

Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases

NCT04870879Not ApplicableUnknownPrimary

Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors

NCT03888638CompletedPrimary

The Role of Tumor-associated Macrophages in Colorectal Liver Metastases

NCT00875147CompletedPrimary

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

NCT00557557Phase 1CompletedPrimary

Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases

NCT02615665CompletedPrimary

Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases

NCT01255007Not ApplicableCompletedPrimary

Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases

NCT02331641CompletedPrimary

Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.

NCT00885950Completed

Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants

Scroll to load more

Research Network

Activity Timeline